Oruka Therapeutics, Inc. (ORKA)
Nasdaq: ORKA · Pharmaceutical Preparations · Menlo Park, CA · filing with the SEC since 1997
Who owns Oruka Therapeutics, Inc.
As filed with the SECHolders of 5% or more
5
Harwin Peter Evan holds 19.5% of Common Stock, $0.001 par value per share, as its SCHEDULE 13D/A filed Jul 1, 2026 says.
Directors and officers
15
report now, of 28 people on the record since 2009. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Harwin Peter Evan
SCHEDULE 13D/A · filed Jul 1, 2026 · Common Stock, $0.001 par value per share · 20% in May 4, 2026
Venrock Healthcare Capital Partners III, L.P.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.001 per share · 9.9% in Nov 14, 2025
Blackrock, Inc.
SCHEDULE 13G · filed Jan 21, 2026 · Common Stock · 4.5% in Oct 17, 2025
Capital World Investors
SCHEDULE 13G · filed Aug 12, 2026 · Common Stock
RTW Investments, LP
SCHEDULE 13G · filed Aug 14, 2026 · Common Stock, $0.001 par value · 4.3% in Feb 17, 2026
Deep Track Capital, LP
SCHEDULE 13G/A · filed Feb 13, 2026 · Common stock, $0.001 Par Value · reported falling below 5%, from 5.07% in May 13, 2025
Viking Global Investors LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.001 par value per share · reported falling below 5%, from 5.3% in May 15, 2026
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%, from 5.06% in Jan 30, 2026
What ORKA reports owning in othersstakes of 5% or more, and other ties
1 subsidiary in 1 country, from the list filed with the 10-K filed Mar 12, 2026.
Insider tradesForm 4
127sales
0purchases
116sales on a scheduled plan
7people selling
$340Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 2, 2025 to Nov 2, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 2, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window7 of 48 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Kiselak Tomas | director | 1 | $300M | 0 | 0 | $0 |
| Klein Lawrence Otto | Chief Executive Officer | 14 | $11.8M | 11 | 0 | $0 |
| Dambkowski Carl | director | 5 | $8.6M | 5 | 0 | $0 |
| Quinlan Paul T | General Counsel | 18 | $7.5M | 15 | 0 | $0 |
| Agarwal Arjun | Senior Vice President, Finance | 30 | $5.1M | 29 | 0 | $0 |
| Goncalves Joana | Chief Medical Officer | 40 | $5.1M | 40 | 0 | $0 |
| Sandler Laura Lee | Chief Operating Officer | 19 | $1.9M | 16 | 0 | $0 |